On September 25, 2015 Array BioPharma Inc. (Nasdaq: ARRY) reported it will hold a conference call to discuss preliminary results from two melanoma trials and a colorectal cancer trial on Monday, September 28, 2015 (Press release, Array BioPharma, SEP 25, 2015, View Source;p=RssLanding&cat=news&id=2090445 [SID:1234507544]). Ron Squarer, Chief Executive Officer, and Victor Sandor, M.D., Chief Medical Officer, will lead the call.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The trials include a Phase 2 combination trial of binimetinib and encorafenib in BRAF-mutant melanoma patients (LOGIC2), a Phase 1b/2 combination trial of binimetinib and a CDK4/6 inhibitor in NRAS-mutant melanoma patients and a Phase 2 combination trial of encorafenib and an EGFR inhibitor with or without the addition of a PI3K inhibitor in patients with BRAF-mutant colorectal cancer. Data from these trials will be presented at the European Society of Medical Oncology (ESMO) (Free ESMO Whitepaper)’s (ESMO) (Free ESMO Whitepaper) annual European Cancer Conference (ECC) or were presented at the 2015 ESMO (Free ESMO Whitepaper) World Congress of Gastrointestinal Cancer.
Conference Call Information
Date: Monday, September 28, 2015
Time: 9:00 a.m. eastern time
Toll-Free: (844) 464-3927
Toll: (765) 507-2598
Pass Code: 43837177
Webcast, including Replay and Conference Call Slides: View Source
– See more at: View Source;p=RssLanding&cat=news&id=2090445#sthash.oer1i36t.dpuf